June 08, 2026 | 10:07
Ractigen Therapeutics has presented late-breaking preclinical data at ADA 2026 showing its LiCO-saUcp1 saRNA therapy converts white fat into calorie-burning brown fat, driving significant fat loss while preserving lean muscle mass and preventing weight rebound.